Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 631-641

  Cordera, Fernando ^a   Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HORMONE ANTAGONIST; LETROZOLE; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TRICHOSTATIN A;

ADD ON THERAPY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; DRUG SUBSTITUTION; ESTROGEN THERAPY; GENE ACTIVATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33751530274     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.020     Document Type: Article

References (106)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2 (1896) 104-107
2. Hwang E.S., Chew T., Shiboski S., et al. Risk factors for estrogen receptor-positive breast cancer. Arch Surg 140 (2005) 58-62
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
4. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344 (2001) 276-285
5. Russo J., and Russo I.H. Genotoxicity of steroidal estrogens. Trends Endocrinol Metab 15 (2004) 211-214
6. Helguero L.A., Faulds M.H., Gustafsson J.A., et al. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24 (2005) 6605-6616
7. Khan S., Rogers M., Obando J., et al. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54 (1994) 993-997
8. Chu K.C., and Anderson W.F. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 74 (2002) 199-211
9. Lawson J., Field A., Champion S., et al. Low oestrogen receptor alfa; expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet 354 (1999) 1787-1788
10. Jensen E.V., and Jordan V.C. The estrogen receptor: A model for molecular medicine. Clin Cancer Res 9 (2003) 1980-1989
11. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365 (2005) 1687-1717
12. Arpino G., Weiss H., Lee A.V., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97 (2005) 1254-1261
13. Anderson W.F., Chu K.C., Chatterjee N., et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 19 (2001) 18-27
14. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 339 (1998) 1609-1618
15. Jordan V.C. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2 (2003) 205-213
16. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 23 (2003) 7512-7517
17. Hull D. III, Clark G., Osborne C., et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 43 (1983) 413-416
18. Gross G., Clark G., Chamness G., et al. Multiple progesterone receptor assays in human breast cancer. Cancer Res 44 (1984) 836-840
19. Balleiner R.L., Earl M.J., Greenberg M.L., et al. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 79 (1999) 1564-1571
20. Kuiper G.G., Enmark E., Pelto-Huikko M., et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93 (1996) 5925-5930
21. Mosselman S., Polman J., and Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392 (1996) 49-53
22. Yang Z., Barnes C.J., and Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10 (2004) 3621-3628
23. Chen J.Q., Delannoy M., Cooke C., et al. Mitochondrial localization of ER{alpha} and ER{beta} in human MCF7 cells. Am J Physiol Endocrinol Metab 286 (2004) E1011-E1022
24. Levin E.R. Cellular functions of plasma membrane estrogen receptors. Steroids 67 (2002) 471-475
25. Faulds M.H., Olsen H., Helguero L.A., et al. Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Mol Endocrinol 18 (2004) 412-421
26. Koehler K.F., Helguero L.A., Haldosen L.-A., et al. Reflections on the discovery and significance of estrogen receptor {beta}. Endocr Rev 26 (2005) 465-478
27. Fuqua S.A., Schiff R., Parra I., et al. Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res 63 (2003) 2434-9243
28. Yang S.-H., Liu R., Perez E.J., et al. Mitochondrial localization of estrogen receptor {beta}. Proc Natl Acad Sci U S A 101 (2004) 4130-4135
29. Bocchinfuso W.P., Lindzey J.K., Hewitt S.C., et al. Induction of mammary gland development in estrogen receptor-{alpha} knockout mice. Endocrinology 141 (2000) 2982-2994
30. Forster C., Makela S., Warri A., et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 99 (2002) 15578-15583
31. Skliris G.P., Parkes A.T., Limer J.L., et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, Western blotting, and flow cytometry in human breast tissue. J Pathol 197 (2002) 155-162
32. Speirs V., Parkes A.T., Kerin M.J., et al. Coexpression of estrogen receptor {{alpha}} and {beta}: Poor prognostic factors in human breast cancer?. Cancer Res 59 (1999) 525-528
33. Speirs V., Malone C., Walton D.S., et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59 (1999) 5421-5424
34. Dotzlaw H., Leygue E., Watson P.H., et al. Estrogen receptor-[β] messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 59 (1999) 529-532
35. Iwao K., Miyoshi Y., Egawa C., et al. Quantitative analysis of estrogen receptor-[β] mRNA and its variants in human breast cancers. Int J Cancer 88 (2000) 733-736
36. Knowlden J.M., Gee J.M.W., Robertson J.F.R., et al. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer 86 (2000) 209-212
37. Shaw J.A., Udokang K., Mosquera J.M., et al. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 198 (2002) 450-457
38. Cullen R., Maguire T.M., McDermott E.W., et al. Studies on oestrogen receptor-[α] and -[β] mRNA in breast cancer. Eur J Cancer 37 (2001) 1118-1122
39. De Cremoux P., Tran-Perennou C., Elie C., et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction: Correlation with protein assays. Biochem Pharmacol 64 (2002) 507-515
40. Bieche I., Parfait B., Laurendeau I., et al. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20 (2001) 8109-8115
41. Park B.W., Kim K.S., Heo M.K., et al. Expression of estrogen receptor-beta in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?. Breast Cancer Res Treat 80 (2003) 79-85
42. Jarvinen T.A.H., Pelto-Huikko M., Holli K., et al. Estrogen receptor [β] is coexpressed with ER[α] and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156 (2000) 29-35
43. Omoto Y., Kobayashi S., Inoue S., et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38 (2002) 380-386
44. Mann S., Laucirica R., Carlson N., et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32 (2001) 113-118
45. Roger P., Sahla M.E., Makela S., et al. Decreased expression of estrogen receptor [β] protein in proliferative preinvasive mammary tumors. Cancer Res 61 (2001) 2537-2541
46. Iwase H., Zhang Z., Omoto Y., et al. Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 52 suppl (2003) S34-S8
47. Konstantinopoulos P.A., Kominea A., Vandoros G., et al. Oestrogen receptor beta (ER[β]) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 39 (2003) 1251-1258
48. Horvath L.G., Henshall S.M., Lee C.S., et al. Frequent loss of estrogen receptor-{beta} expression in prostate cancer. Cancer Res 61 (2001) 5331-5335
49. Skliris G.P., Parkes J., Limer J.L., et al. Evaluation of seven oestrogen receptor?. antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 197 (2002) 155-162
50. McInerney E.M., Weis K.E., Sun J., et al. Transcription activation by the human estrogen receptor subtype {beta} (ER{beta}) studied with ER{beta} and ER{alpha} receptor chimeras. Endocrinology 139 (1998) 4513-4522
51. Hall J.M., and McDonnell D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 (1999) 5566-5578
52. Duong V., Licznar A., Margueron R., et al. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 9 (2005) 1-8
53. Leong H., Sloan J.R., Nash P.D., et al. Recruitment of Histone Deacetylase 4 to the N-terminal region of estrogen receptor {alpha}. Mol Endocrinol 19 (2005) 2930-2942
54. Jang E.R., Lim S.J., Lee E.S., et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23 (2004) 1724-1736
55. Pandolfi P.P. Transcription therapy for cancer. Oncogene 20 (2001) 3116-3127
56. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1 (2001) 194-202
57. Margueron R., Duong V., Bonnet S., et al. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol 32 (2004) 583-594
58. Kramer O.H., Gottlicher M., and Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12 (2001) 294-300
59. Osborne C.K., and Schiff R. Estrogen-receptor biology: Continuing progress and therapeutic implications. J Clin Oncol 23 (2005) 1616-1622
60. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 20 (1999) 321-344
61. Wang Z., Rose D.W., Hermanson O., et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A 97 (2000) 13549-13554
62. List H.-J., Lauritsen K.J., Reiter R., et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276 (2001) 23763-23768
63. Torres-Arzayus M.I., de Mora J.F., Yuan J., et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6 (2004) 263-274
64. Kuang S.-Q., Liao L., Zhang H., et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 64 (2004) 1875-1885
65. Labhart P., Karmakar S., Salicru E.M., et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci U S A 102 (2005) 1339-1344
66. Lavinsky R.M., Jepsen K., Heinzel T., et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 95 (1998) 2920-2925
67. Simon S.L.R., Parkes A., Leygue E., et al. Expression of a repressor of estrogen receptor activity in human breast tumors: Relationship to some known prognostic markers. Cancer Res 60 (2000) 2796-2799
68. Steffi O. Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?. J Cell Biochem 90 (2003) 653-661
69. Zheng L., Annab L.A., Afshari C.A., et al. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 98 (2001) 9587-9592
70. Huang G., Song Y., and He G. [mRNA expression and mutation of MTA1 and nm23H1 genes in ovarian carcinoma in relation to lymph node metastasis]. Zhonghua Zhong Liu Za Zhi 23 (2001) 31-34
71. Schiff R., Reddy P., Ahotupa M., et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92 (2000) 1926-1934
72. Keen J.C., and Davidson N.E. The biology of breast carcinoma. Cancer 97 suppl (2003) 825-833
73. Graham J.D., Roman S.D., McGowan E., et al. Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem 270 (1995) 30693-30700
74. Yang X., Phillips D.L., Ferguson A.T., et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61 (2001) 7025-7029
75. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
76. Nahta R., Yuan L.X., Zhang B., et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 (2005) 11118-11128
77. Matsui Y., Halter S.A., Holt J.T., et al. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61 (1990) 1147-1155
78. Zhu L., Chow L.W.C., Loo W.T.Y., et al. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial. Clin Cancer Res 10 (2004) 4639-4644
79. Osborne C.K., Bardou V., Hopp T.A., et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95 (2003) 353-361
80. Witton C.J., Reeves J.R., Going J.J., et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200 (2003) 290-297
81. Cormier E., Wolf M., and Jordan V. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 49 (1989) 576-580
82. Cormier E.M., and Jordan V.C. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur J Cancer Clin Oncol 25 (1989) 57-63
83. Robinson S.P., and Jordan V. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: Possible role of antiestrogen failure. Eur J Cancer Clin Oncol 25 (1989) 493-497
84. Robinson S.P., and Jordan V.C. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49 (1989) 1758-1762
85. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90 (1998) 1371-1388
86. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA 281 (1999) 2189-2197
87. Miller W.R. Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer. Semin Oncol 30 suppl 14 (2003) 3-11
88. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
89. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
90. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 (2005) 5138-5147
91. ATAC Trialists' Group. L Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
92. Wakeling A.E., Dukes M., and Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 51 (1991) 3867-3873
93. Dauvois S., White R., and Parker M. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106 (1993) 1377-1388
94. Carlson R.W. The history and mechanism of action of fulvestrant. Clin Breast Cancer 6 suppl 1 (2005) 5-8
95. Howell A., Robertson J.F., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 22 (2004) 1605-1613
96. Bross P.F., Cohen M.H., Williams G.A., et al. FDA drug approval summaries: Fulvestrant. Oncologist 7 (2002) 477-480
97. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
98. Stewart H.J., Forrest A.P., Everington D., et al., The Scottish Cancer Trials Breast Group. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 74 (1996) 297-299
99. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
100. Fuqua S.A.W., and Schiff R.T. The biology of estrogen receptors. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). (eds): Diseases of the Breast (ed 3) (2004), Lippincott Williams & Wilkins, Philadelphia, PA 585-602
101. Berstein L.M., Wang J.P., Zheng H., et al. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res 10 (2004) 1530-1534
102. Yao K., Bentrem D.J., England G., et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6 (2000) 2028-2036
103. Liu H., Lee E.-S., Gajdos C., et al. Apoptotic action of 17{beta}-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95 (2003) 1586-1597
104. Lewis J.S., Meeke K., Osipo C., et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97 (2005) 1746-1759
105. Osipo C., Gajdos C., Liu H., et al. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95 (2003) 1597-1608
106. Lonning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67 (2001) 111-116